Tablet Presentation

Each Uncoated Tablet Contains:
Metformin Hydrochloride(as Prolonged Release) IP 500 mg
Glimepiride 1mg/2mg

This composition is used together for the lowering the risk of decrease in blood sugar level i.e. hypoglycaemia which occurs due to single use of glimepiride which can be adjusted by using it with metformin.


    In type-2 diabetes mellitus

About Composition


Metformin belongs to the biguanides class. It is antihyperglycemic drug and is used in the treatment of the Type-2 diabetes mellitus.
It does not cause hypoglycaemia which is the side effect of other antihyperglycemic drugs
Metformin decreases the insulin resistance
It is very effective when taken during exercise and with diet


Glimepiride is known as insulin secretagogue. It improves the glycaemic control
It lowers the blood glucose level.

Mechanism of Action

Metformin decreases the production of glucose by liver and prevents the intestinal absorption of glucose Also enhances the insulin sensitivity by increasing peripheral glucose uptake and utilization. Glimepiride binds to SUR receptors blocks the ATP sensitive potassium channels and causes depolarization of beta cells.



It is absorbed orally and d not show protein binding and metabolism. it is excreted unchanged in the urine.


It is orally absorbed and it is 99% bound to plasma proteins
It undergoes oxidation and excreted via urine

Side Effects

  • Nausea
  • Dizziness
  • Weakness
  • Headache
  • Weight gain


  • Contraindicated in renal dysfunction
  • Contraindicated in people with known hypersensitivity

Drug Interactions

  • Digoxin
  • Quinidine
  • Procainamide

Disclaimer:The data uploaded is made from content already available on internet.The company holds no right of it and is not responsible for any wrong information.

Know About new DCGI Approved Products